Genetic Testing, InvisionFirst Liquid Biopsy for Lung Cancer
Customize your policy alerts
Sign up for Presbyterian Health Plan Policy 39.1 alerts
Get alerted when Policy 39.1 changes without checking for updates manually.
Monitor payer policy activity
Coverage and prior authorization for blood-based InVisionFirst ctDNA liquid biopsy testing supporting therapeutic decisions in advanced NSCLC for Commercial, Medicaid, and Medicare members, subject to the member-specific benefit plan and policy criteria.
The 2026 annual review clarified that plasma ctDNA testing is not medically necessary for initial NSCLC diagnosis and is covered only when invasive tissue biopsy is medically inappropriate or tissue is insufficient for molecular analysis.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.